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Abstract
Both Akt and Aurora A kinase have been shown to be important targets for intervention for cancer therapy. We
report here that Compound A (A-443654), a specific Akt inhibitor, interferes with mitotic progression and bipolar
spindle formation. Compound A induces G2/M accumulation, defects in centrosome separation, and formation of
either monopolar arrays or disorganized spindles. On the basis of gene expression array studies, we identified
Aurora A as one of the genes regulated transcriptionally by Akt inhibitors including Compound A. Inhibition of
the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, either by PI3K inhibitor LY294002 or by Compound A, dra-
matically inhibits the promoter activity of Aurora A, whereas the mammalian target of rapamycin inhibitor has little
effect, suggesting that Akt might be responsible for up-regulating Aurora A for mitotic progression. Further anal-
ysis of the Aurora A promoter region indicates that the Ets element but not the Sp1 element is required for Com-
pound A–sensitive transcriptional control of Aurora A. Overexpression of Aurora A in cells treated with Compound
A attenuates the mitotic arrest and the defects in bipolar spindle formation induced by Akt inhibition. Our studies
suggest that that Akt may promote mitotic progression through the transcriptional regulation of Aurora A.
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Introduction
The Akt protein plays a critical role in preventing cells from under-
going apoptosis [1]. Akt is a serine/threonine kinase originally iden-
tified as a cellular homolog of the viral oncogene Akt8. The three
isoforms of Akt (Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ) share
a high degree of structural similarity and sequence homology. The
current model suggests that Akt is activated through the phosphati-
dylinositol 3-kinase (PI3K) pathway on growth factor stimulation.
The products of PI3K, especially phosphatidyl inositol (3,4,5) tri-
phosphate, bind to the Pleckstrin homology domain of Akt and tar-
get Akt to the plasma membrane where it is phosphorylated on two
key residues: Thr308 in the activation loop by PDK1 [2] and Ser473
in the hydrophobic motif of the C-terminal tail by putative PDK2.
Proposed candidates of PDK2 include PDK1 [3], integrin-linked ki-
nase [4], Akt itself [5], DNA-PKcs [6], and recently, the mammalian
target of rapamycin–rictor complex [7]. Phosphorylation on both
Thr308 and Ser473 is required for full activation of Akt [1,2, and
the references therein].
Several substrates for Akt have been identified, including Bad, cas-
pase-9, forkhead transcription factors, IκB kinase kinase, glycogen
synthase kinase 3 (GSK3), MDM2, p21cip1/WAF1, TSC2, and so
on [1,8]. Among these, Bad, caspase-9, and forkhead transcription
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factors facilitate apoptosis, and the phosphorylation by Akt abolishes
their proapoptotic activities [1,8].
PI3K–Akt transduces mitogenic signals from growth factors and pro-
motes G1/S transition. Through multiple mechanisms, Akt down-
regulates p27, an important Cdk inhibitor that halts cells in late G1 until
cells are ready for DNA synthesis [9–11]. In addition, the PI3K–Akt
pathway also regulates the transition at G2/M. Either PI3K inhibitors
or the absence of Akt in Akt1-null ES cells were reported to induce a
delay in G2/M transition [12–14]. The PI3K–Akt pathway has been
shown to regulate mitotic entry in addition to its mitogenic functions
at the G1/S transition. Inhibition of PI3K results in a delay in the pro-
gression through G2/M, which can be rescued by overexpressing Akt
[12–14]. PTEN-null ES cells were shown to transit faster through the
G2/M phase [12]. Overexpressing a dominant-negative mutant of Akt
also arrests cells in G2/M [15]. Finally, PI3K–Akt pathway regulates mi-
totic entry through controlling the timing of Cdc2 activation [16].
Wee1 and Myt1 are two kinases that phosphorylate Cdc2 at Thr14/
Tyr15 and inhibit Cdc2 kinase activity. Akt phosphorylates and down-
regulates Myt1 at the G2/M boundary [17]. In addition, Akt was shown
to phosphorylateWEE1Hu at Ser642, which in turn provides the binding
site for 14-3-3θ. This 14-3-3θ binding translocates WEE1Hu into the
cytoplasm and, thus, prevents its inhibitory phosphorylation on Cdc2
[18]. Akt also prevents Plk1 degradation through CHFR and promotes
mitotic entry under normal conditions and after DNA damage [19].
Aurora kinases are serine/threonine kinases that regulate mitotic
events, ranging from centrosome maturation, mitotic spindle forma-
tion, chromosome segregation to cytokinesis [20–23]. The three
members of Aurora kinase family in metazoans share extensive struc-
ture and sequence similarities [20–23]. However, they show distinct
localizations and functions during mitosis. Aurora A localizes to cen-
trosomes and is essential for centrosome duplication and maturation
[20–23]. Overexpression of Aurora A leads to genomic instability and
neoplastic transformation, demonstrating that Aurora A is a bonafide
oncogene [24–26]. Cells depleted of Aurora A by siRNA are arrested at
mitosis [27,28] and display a G2 delay in synchronized cells [28]. Au-
rora B is localized to centromeres in early mitosis, relocates to the cen-
tral spindle in anaphase and the spindle midzone during telephase, and
finally migrates to themidbody during cytokinesis [20–22,29]. Aurora
B functions as a chromosome passenger protein involved in chro-
mosome condensation, kinetochore–microtubule attachment, chro-
mosome alignment in metaphase, and midbody function during
cytokinesis [20–22]. Aurora C is also associated with the centrosomes,
but its function in mitosis is not well defined [21,22].
We have previously identified a potent and selective Akt inhibitor,
hereafter referred to as Compound A (A-443654) [30,31]. Here, we
show that Compound A induces mitotic arrest and defects in spindle
formation in cells, consistent with an Aurora A–deficient phenotype,
whereas its enantiomer (Compound B) does not. Akt inhibition was
found to down-regulate Aurora A expression. Overexpression of Au-
rora A rescues the mitotic defect induced by Akt inhibition. Our data
suggest a novel mechanism in which Akt promotes mitotic progres-
sion through the transcriptional regulation of Aurora A.
Materials and Methods
Cell Lines Agents
All chemicals were purchased from Sigma (St. Louis, MO).
H1299, MiaPaca-2, and HeLa cells were obtained from American
Type Culture Collection (Manassas, VA).
Plasmids
The 1.8-kb DNA fragment corresponding to −1486 to +355 of
the 5′-flanking region of Aurora A gene [32] was polymerase chain
reaction amplified from genomic DNA isolated from normal human
fibroblast using the Qiagen genomic DNA isolation kit (Qiagen,
Valencia, CA). The fragment was gel-purified and cloned into the BglII
site of pGL3-basic (Promega, Madison, WI) to obtain pGL-1.8kb.
Various constructs were subcloned from pGL-1.8kb. For pCDNA.3.
Aurora A, polymerase chain reaction fragment–encoded Aurora A was
cloned between the BamHI and XhoI sites in pcDNA3.1/myc-His A
(Invitrogen, Carlsbad, CA). The resulting construct encodes Aurora
A with both a myc tag and a polyhistidine tag at the C-terminus. All
the inserted DNA fragments and generated mutations were confirmed
by sequencing.
Cell Transfection and Luciferase Assay
H1299 cells in a density of 1 × 104 per well in 96-well black plates
(Cat# 7716-2380; Whatman, Clifton, NJ) were transiently trans-
fected with 0.3 μg of various plasmids using Lipofectamine 2000
(Cat# 11668-027; Invitrogen). Luminescence was determined using
Steady-Glo Reagent (Cat# E2510; Promega) according to the man-
ufacturer’s protocol.
Immunofluorescence
Cells were cultured in Lab-Tek-2 chamber slides (Cat# 155382;
Nalge Nunc International, Rochester, NY) at 4 × 104 per chamber.
After incubation with Compound A or B for 24 hours, the cells were
fixed and permeabilized with methanol/acetone (50:50) for 20 min-
utes and blocked with a blocking solution (3% bovine serum albu-
min in PBS) for another 20 minutes. The cells were then incubated
sequentially with the following antibodies for 2 hours in a blocking
buffer with three times of washes in between: rabbit polyclonal
anti–γ-tubulin antibody (at 1:500, Cat# T3559; Sigma), donkey
antirabbit IgG(H+L) conjugated with Alexa Fluor 555 (at 1:500,
Cat# A31572; Invitrogen), and monoclonal anti–α-tubulin–fluorescein
isothiocyanate antibody (at 1:100, Cat# F2168; Sigma). Finally, the
cells were covered with mounting medium Prolong Gold antifade
reagent with DAPI (Cat# P36935; Invitrogen), sealed with cover-
slips, counted, and photographed with a microscope (Axiovert 200M;
Carl Zeiss, Inc, Chester, VA). All the procedures were performed at
room temperature.
Flow Cytometry Analysis
Cells were harvested by pooling attached and detached cells and
pelleted by centrifugation at 800g for 5 minutes at 4°C. The cells
were washed with PBS and resuspended in 0.5 ml of ice-cold staining
solution (5 μg/ml propidium iodide, 40 U/ml RNase A, 0.5% Triton
X-100, in PBS). After 1 hour at 4°C in the dark, the DNA content
was analyzed using a Beckton Dickinson ExCalibur Flow Cytometer
(San Jose, CA).
Western Blot Analysis
Cells were harvested and lysed in buffer B (20 mM HEPES, pH
7.5, 10 mM NaCl, 20 mM NaF, 1 mM EDTA, 1 mM EGTA,
5 mM sodium pyrophosphate, 2 mM sodium vanadate, 10 mM β-
glycerophosphate, and 1% NP-40) on ice for 30 minutes. The samples
were centrifuged at 12,000g at 4°C for 10 minutes. The supernatants
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were used as cell extracts. Rabbit anti–Aurora A, anti–Aurora B, and
anti–histone H3 antibodies were purchased from Cell Signaling
Technology, Inc (Beverly, MA). Anti-actin, anti-PLK1, and anti–cyclin
B1 antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
Microarray Analysis
Total RNA was extracted from MiaPaca-2 cells treated with in-
hibitors for 5 hours (n = 2 for each treatment). The total RNA were
intact as judged by Agilent 2100 analysis (Agilent Technologies,
Santa Clara, CA). Approximately 8 μg of total RNA from each
sample was used to prepare biotin-labeled cRNA target using stan-
dard Affymetrix protocols. The Affymetrix Human chip U133Av2
(Affimetrix, Santa Clara, CA) was used, and 10 μg of cRNA target
was applied to each array. Scanned images were loaded into the
Rosetta Resolver 4.0 database (Rosetta Biosoftware, Seattle, WA)
and processed using the Resolver Affymetrix error model. The repli-
cates (n = 2) of drug-treated samples were informatically combined
within Resolver and ratios constructed relative to the combined
DMSO controls. A combination of classification, clustering, gene
ontology, and pathway mapping analyses were used to assess the
function of the regulated genes.
Results
Inhibition of Akt Results in Mitotic Arrest
Compound A is a potent and selective Akt inhibitor with a K i of
160 pM against Akt1, and it is equally potent against Akt2 and Akt3
in cells. Compound B, the enantiomer of Compound A, is much less
active than Compound A against Akt but has very similar activities
against other kinases (Figure 1A) [30,31]. Compound A inhibits Akt
in H1299 cells at 0.6 μM as demonstrated by its ability to inhibit
the phosphorylation of GSK3α/β, whereas Compound B does not,
Figure 1. Akt inhibition down-regulates Aurora A and inducesmitotic arrest. (A)Western analysis of P-GSK3α/β and total GSK3α/β in H1299
cells treatedwith Compound A or B at 0.6 μMconcentration for 2 hours. (B) FACS analysis of H1299 cells treatedwith Compound A or B for
24 hours. (C) MiaPaca-2 cells were treated with Compound A or B at the indicated concentrations for 5 hours. Total RNA was isolated and
subjected to microarray analysis as described. The fold changes compared to the DMSO control in Aurora A mRNA levels were listed. (D)
MiaPaca-2 cells were treated with Compound A at the indicated concentrations for 24 hours. The cells were harvested, and Western blot
analysiswas carried out. Aurora A levelswere quantified from three experiments usingGS-800 calibrated densitometer (Bio-Rad, Hercules,
CA) and listed beneath each western gels. Student’s t test were performed and *P< .05 or **P< .01 is obtained between the control and
themarked lane. (E) H1299 cellswere treatedwith CompoundAor B at 0.6 μMfor 24 hours. The cellswere harvested, andWestern analysis
was carried out. Statistical analysiswas done as in (D). (F) H1299 cells were treatedwith CompoundA at 0.6 μMfor the indicated times. The
cells were harvested, and Western analysis was carried out. (G) H1299 cells were treated with Compound A at 0.6 μM in the presence or
absence of 20 μMMG132 for 24 hours. The cells were harvested, andWestern analysiswas carried out. (H) HCT116 cells were treatedwith
Compound A or B at 0.5 μM for 24 hours. The cells were harvested, and Western analysis was carried out.
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and thus, Compound B provides a control for Compound A (Fig-
ure 1A) [30,31]. Similar concentrations of Compound A induced
G2/M accumulation in H1299 cells, whereas compound B did not,
suggesting that the G2/M accumulation is due to Akt inhibition
(Figure 1B). Similar G2/M accumulation was also observed with other
Akt inhibitors such as Compound C [31] (data not shown) or in other
cell lines regardless whether the cells have wild type p53 (HCT116
and RKO) or have defective p53 functions (RKO-E6, MiaPaCa,
and HeLa; data not shown). Compound A is very selective and only in-
hibits mitotic kinases at very high concentrations. The selectivity com-
pared to its activity toward Akt are at least 3800-fold for Aurora A,
Aurora B, Plk1, Plk3, and Plk4. Its selectivity against Cdc2 versus Akt
is 280-fold. Therefore, it is unlikely that the G2/M accumulation in-
duced by Compound A is due to a direct inhibition of mitotic kinases.
Inhibition of Akt Reduces the mRNA and
Protein Levels of Aurora A
To explore the mechanism of mitotic regulation by Akt, we carried
out microarray experiments with Compounds A and B and identified
Aurora A as one of the genes regulated by Akt. Aurora A mRNA levels
were significantly reduced when Akt was inhibited in cells by Com-
pound A but not by Compound B at 0.3 μM in MiaPaca-2 cells, the
concentration at which Akt is inhibited by Compound A in this cell
line [30,31] (Figure 1C ). Aurora A kinase is one of the nine genes
that showed dose-dependent regulation by Compound A between
0.1 and 0.3 μM, whereas no genes showed dose-dependent regula-
tion by Compound B within the same concentration range (data not
shown). This suggests that Aurora A kinase is one of the most prom-
inently regulated genes by Akt. The protein levels of Aurora A were
also reduced in the cells treated with Compound A in a concentration-
dependent manner in MiaPaca-2 (Figure 1D). In H1299 cells, Com-
pound A reduced the protein level of Aurora A but not other mitotic
proteins including Aurora B, PLK1, and cyclin B1 (Figure 1E). Com-
pound A reduced the protein level of Aurora in a time-dependent
manner (Figure 1F ). Inclusion of MG132 inhibited Compound
A–medicated reduction of Aurora A, indicating the involvement of
proteasome pathway in the process (Figure 1G ). Similar inhibition
of Aurora A by Compound A was also observed in HeLa cells at
the same concentration that induces G2/M accumulation (data not
shown). Compound A–mediated reduction of Aurora A was indepen-
dent of the status of p53, because Compound A showed the same
effect in HCT116 cells which has a wild type p53 (Figure 1H).
Akt Regulates the Promoter Activity of Aurora A
We cloned the Aurora A promoter region corresponding to −1486
to +355 of the 5′-flanking sequence into a luciferase reporter vector
pGL3 [32] and assigned it as pGL-1.8kb. pGL-556bp, a truncation
of pGL-1.8kb containing the Sp1 and Ets elements, was also gener-
ated (Figure 2A). Transient transfection experiment in H1299 cells
showed that both constructs had high levels of promoter activity (Fig-
ure 2B). In fact, pGL-556bp showed better activity than pGL-1.8kb,
Figure 1. (continued).
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indicating that there may be an inhibitory element located in the re-
gion corresponding to −1486 to −196 of the Aurora A promoter. The
luciferase activities from both pGL-1.8kb and pGL-556bp were in-
hibited by LY294002 (Figure 2C ) and Compound A (Figure 2E ) in
a concentration-dependent manner, whereas rapamycin had little ef-
fect (Figure 2D).
Akt Regulates Aurora A Expression through the Ets Element
To identify the transcription element that is responsible for the
Akt-mediated regulation of Aurora A, a series of truncated constructs
were generated (Figure 3A). The Ets element is necessary for the ac-
tivity but is not sufficient because pGL-53bp and pGL-8bp lost the
activity. It needs a longer length either at 5′ or 3′ end for full activity,
which may reflect a requirement for a sufficient space for transcrip-
tion factor binding. The shortest fragments that retained most of the
activity are −107 ∼+40 or −196 ∼−55 in pGL-147bp or pGL-142bp,
respectively (Figure 3, B and C ). The Sp1 site, however, is not nec-
essary because pGL-147bp retained most of the activity (Figure 3C ).
The luciferase activities from pGL-147bp and pGL-142bp can be
inhibited by Compound A (Figure 3, D and E ). Compound A in-
hibited 91% and 92% of the luciferase activity of pGL-147bp and
pGL-142bp, respectively, at the concentration of 0.6 μM (Figure 3,
D and E ). At 0.6 μM, although Compound B inhibited 45% and
51% of the luciferase activity of pGL-147bp and pGL-142bp, re-
spectively (Figure 3, D and E ), this was not sufficient for Aurora
A protein reduction (Figure 1E ). Therefore, Compound A blocked
Aurora A protein expression, whereas Compound B did not at
this concentration.
The luciferase activities decreased significantly in four constructs
containing the mutations of the Ets element, pGL-147-M1, pGL-
147-M2, pGL-142-M1, and pGL-142-M2 (Figure 4, A and B).
Conversely, pGL-142-M3 with an Sp1 mutation retained all the ac-
tivity of wild type pGL-142 (Figure 4, C and D), suggesting that Sp1
is not necessary for such an activity of the Aurora promoter. Similar
data were obtained in HeLa cells (data not shown).
Akt Inhibition Induces Abnormal Mitosis
We used H1299 cells for further mitotic phenotype studies be-
cause H1299 cells give nice mitotic morphology. Compound A in-
hibited Akt and induced a significant increase in the mitotic index in
H1299 as measured by condensed chromosomes and spindle forma-
tion (Figure 5A). We observed that most of the mitotic cells treated
with Compound A contained abnormal spindle formation consisting
of rosette (second row) or monopolar arrays (third row) instead of
Figure 2. Identification of the Akt-response element in Aurora A promoter. (A) Schematic representation of the Aurora A promoter-lu-
ciferase constructs. (B) H1299 cells were transiently transfected with pGL-1.8kb or pGL-556bp, and the luciferase activities were as-
sessed 24 hours after transfection. (C, D, and E) H1299 cells were transfected with pGL-1.8kb and pGL-556bp. Approximately 8 hours
later, LY294002 (C), rapamycin (D), or Compound A (E) was added, and the luciferase activities were assessed 24 hours later.
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Figure 3. Identification of Ets as the Akt-response element. (A) Schematic representation of the Aurora A promoter luciferase constructs.
(B and C) H1299 cells were transfected with the indicated Aurora A promoter constructs at indicated concentrations. Experiments were
done as in Figure 2. Data are representative of three independent experiments. (D and E) H1299 cells were transfected with either pGL-
147bp (D) or pGL-142bp (E). Approximately 8 hours later, Compound A or B was added, and the luciferase activities were assessed
24 hours later.
Figure 4. Mutational analysis of Ets and Sp1 elements. (A and C) DNA sequences of the wild type and the mutated Ets or Sp1 se-
quences. The underlined sequences are either the Ets or the Sp1 sites, and the nucleotides in bold are the mutated nucleotides. (B
and D) H1299 cells transfected with the indicated constructs, and luciferase activities were analyzed 24 hours after transfection. Data
are representative of three independent experiments.
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normal bipolar spindles as in the control cells (Figure 5B). Bipolar
spindles could also form in cells treated with Compound A (fourth
row). However, the bipolar spindles were not aligned well and, as in
the cells with rosette or monopolar spindles, chromosomes were not
aligned at the equators as are those in normal controls (Figure 5B).
Quantitative analysis indicated that abnormal spindle formation
(monopolar spindles or disorganized array) dramatically increased
in Compound A–treated cells (Figure 5C ). Therefore, in addition
to regulating mitotic entry [12–14], Akt also regulates centrosome
separation and spindle formation during premetaphase. Aurora A
deficiency results in defects in centrosome separation and biopolar
spindle formation [33–35]. The abnormal mitotic phenotypes we
observed here with Akt inhibition are consistent with the Aurora A
kinase null phenotypes.
Overexpression of Aurora A Partially Rescues the Mitotic Arrest
Induced by Akt Inhibition
To examine whether Akt inhibition induces mitotic arrest through
Aurora A down-regulation, we overexpressed Aurora A to determine
whether it could rescue the mitotic arrest induced by Compound A
treatment. Aurora A kinase was transiently overexpressed from a
CMV promoter using a pcDNA vector, which is not regulated by
Akt (Figure 6A). We treated these cells with Compound A and an-
alyzed cell cycle progression. As shown in Figure 6B, G2/M accumu-
lation was significantly reduced in Aurora A–overexpressing cells
when compared to that in cells transfected with vector alone after
Compound A treatment. In addition, the population of abnormal
mitotic cells was also reduced in Aurora A–overexpressing cells
(Figure 6C ). We estimated that 50% of the cells were transfected
Figure 5. Inhibition of Akt results in abnormal mitosis. H1299 cells were treated with Compound A or B at 0.6 μM for 24 hours. (A)
Mitotic index was scored on the basis of chromosome condensation, disappearance of nuclear membrane, and spindle formation.
(B) Typical examples of normal and abnormal mitotic cells. (C) Quantitative assessment of normal and abnormal mitotic spindles. For
each treatment condition, more than 150 mitotic cells were scored. Data are representative of three independent experiments.
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by cotransfecting a GFP coding construct (data not shown). In the
transfected cell population, the mitotic defect can be reversed by the
expression of Aurora A to almost the levels in the vehicle controls
(Figure 6D). Therefore, the mitotic defects induced by Akt inhibitor
Compound A are consistent with the Aurora A–deficient pheno-
types, and these defects were rescued by overexpressing Aurora A.
This suggests that Akt may modulate mitotic progression, at least
partly, through Aurora A regulation.
Discussion
Aurora A is essential for centrosome maturation, separation, and
bipolar spindle formation [23,28,33,35–39]. We have shown that an
Akt inhibitor (Compound A) induces a G2/M arrest at a concentra-
tion that inhibits Akt in cells [31], whereas its enantiomer (Com-
pound B) at the same concentration does not (Figures 1 and 5). In
addition to the defects in mitotic entry reported with PI3K inhibitors
or Akt inhibitors in the literature, we observed that a significant por-
tion of those cells was arrested in mitosis (Figure 5A). The presence
of abnormal spindles, such as monopolar arrays due to the defect in
centrosome separation, or disorganized spindles (Figure 5, B and C )
is consistent with the Aurora A defect [33–35,40]. Exogenous expres-
sion of Aurora A in cells treated with Compound A rescues the spin-
dle formation defects and the mitotic arrest (Figure 6), suggesting
that the mitotic defects induced by Akt inhibition are, at least partly,
due to the inability to express Aurora A kinase in cells. Thus, Akt
regulates mitotic entry as well as bipolar spindle formation through
controlling Aurora A expression. Our data are consistent with the
earlier report that an Akt activity blocker, 1L-6-hydroxy-methyl-
chiro-inositol 2-2-O-methyl-3-O-octadecylcarbonate, and the PI3K
inhibitor, LY294002, delay mitotic cells progressing into G1 phase
of the next cycle [15]. We also tried to strengthen our finding using
Akt1 siRNA. Although Akt1 siRNA were able to reduce approxi-
mately 70% of Akt1 protein in H1299 cells, it has no effect on
the phosphorylation of GSK3 and aurora A (data not shown). This
is probably due to the reason that either Akt1 protein level was not
reduced enough or Akt2/3 might be able to compensate for the loss
of Akt1 efficiently in H1299 cells. In fact, only a small portion of Akt
is active in wild type MEF cells, and Akt1 is able to compensate for
the loss of Akt3 in its prosurvival activity [41]. Because Compound A
is a pan-Akt inhibitor, it is likely that all isoforms of Akt have to be
inhibited to see the reduction of Aurora A.
Akt inhibitor (Compound A) interferes with the proper formation
of the bipolar spindle during mitosis by controlling the transcription
of the Aurora A gene. We showed that the Ets element located in the
Aurora A promoter region is necessary but not sufficient for such a
regulation. The PI3K–Akt pathway has been shown to positively or
negatively regulate various Ets transcription factors depending on the
Figure 6. Overexpression of Aurora A rescues the mitotic defects induced by Akt inhibition. (A) H1299 cells were transfected with
pcDNA3.1 or pcDNA3–Aurora A. Cell extracts were prepared 24 hours after transfection and were subjected to Western blot analysis.
(B and C) H1299 cells were transfected as described in (A). The cells were then treated with DMSO, 0.6 μM Compound A or B for
24 hours. Cells were stained with propidium iodide for FACS analysis or were immunostained with DAPI and antibodies against α-
and γ-tubulins. FACS analysis (B) and abnormal mitosis (C) were scored as described. For each condition, more than 150 mitotic cells
were scored. Data are average of three independent experiments. (D) Experiment was done as in (C) except 0.8 μg of padtrack-GFP was
cotransfected with pcDNA3.1–Aurora A. GFP were immunostained with fluorescein isothiocyanate–conjugated GFP antibody (Abcam,
Cambridge, MA). Only GFP-positive cells (60–100 cells) were scored.
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individual Ets factors [42–44]. Further studies are warranted to
search for the Ets factor(s) responsible for Akt-directed regulation
of Aurora A expression. Interestingly, Akt was shown to phosphory-
late CHFR, preventing its potential role in Plk1 degradation [19].
CHFR is also implicated in degradation of Aurora A [45], providing
yet another potential venue for Akt to regulate Aurora A protein
levels. In addition, overexpression of Aurora A induces the activation
of Akt through a p53-dependent manner [46,47], indicating that
there is a positive feedback interplay between Akt and Aurora A.
These findings have potential impact on the strategies used in de-
veloping Akt inhibitors as therapeutics. Although additional toxicities
may be associated with the Aurora A suppression, the benefit of in-
hibiting Aurora A in tumor cells, especially those that overexpress
Aurora A, could supercede the risk of toxicity [48]. Our data also
suggest the cancer patients that overexpress Aurora A may serve as
a suitable population for using Akt inhibitors in the clinic.
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